A Study of SGN-ALPV in Advanced Solid Tumors

Inclusion Criteria:

Participants must have one of the following histologically or cytologically confirmed metastatic or unresectable solid tumor types:

Parts A and B

Ovarian cancer
Endometrial cancer
Non-small cell lung cancer (NSCLC)
Gastric cancer
Cervical cancer
Malignant testicular germ cell tumor (GCT), except for pure teratomas
Malignant ovarian GCT, except for pure teratomas

Part C

High-grade serous ovarian cancer (HGSOC): Participants must have HGSOC which has progressed or relapsed within 6 months after previous platinum containing chemotherapy, received 2 to 4 prior anticancer lines of therapy, and at least 1 line of therapy in the platinum-resistant setting. If eligible at least 1 line of therapy must have contained bevacizumab or a biosimilar to bevacizumab.
Endometrial Cancer: Participants must have unresectable locally advance or metastatic endometrial carcinoma and have had at least 1 prior line of therapy.
NSCLC: Participants must have unresectable locally advanced or metastatic NSCLC and have received platinum-based therapy and a PD-(L)1 inhibitor.
Gastric cancer: Participants must have unresectable locally advanced or metastatic gastric cancer and have received prior platinum and fluoropyrimidine -based chemotherapy

Participants enrolled in the following study parts should have an appropriate tumor site and agree to a biopsy

Disease-specific expansion cohorts, subjects 16 onwards: pretreatment biopsy.
Biology expansion cohort: pretreatment biopsy, on-treatment biopsy during Cycle 1, and end of treatment biopsy.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Measurable disease per the RECIST v1.1 at baseline

Exclusion Criteria:

History of another malignancy within 3 years of first dose of study treatment or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
Known active central nervous system metastases.
Previous receipt of an MMAE-containing agent or an agent targeting ALPP or ALPPL2.
Pre-existing neuropathy ≥ Grade 2 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0